Send us Feedback

Sunesis Pharmaceuticals (SNSS)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Sunesis to Host Conference Call on May 15th to Discuss First Quarter Financial Results and Recent Highlights
Globe Newswire  May 8  Comment 
SOUTH SAN FRANCISCO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, May 15th, 2012 at 11:00 a.m. Eastern Time to discuss corporate updates and
Sunesis Pharmaceuticals Receives European Orphan Drug Designation for Vosaroxin to Treat Acute Myeloid Leukemia
Globe Newswire  May 3  Comment 
SOUTH SAN FRANCISCO, Calif., May 3, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the European Commission has granted orphan drug designation to vosaroxin, the Company's lead development candidate, for the
Sunesis to Present at the 19th Annual Future Leaders in the Biotech Industry Conference
Globe Newswire  Apr 13  Comment 
SOUTH SAN FRANCISCO, Calif., April 13, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the 19th Annual Future Leaders in the Biotech
Notable 52-Week Highs and Lows of the Day 03/30: (LIZ) (THLD) (SNSS) High; (SVU) (TSTC) Low
StreetInsider.com  Mar 30  Comment 
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today. 52-Week High: Liz Claiborne Inc. (NYSE: LIZ) high of $15.39. Liz ripped Friday afternoon amid chatter the company might be...
Unusual 11 Mid-Day Movers 03/30: (SNSS) (ZAZA) (TWER) Higher; (FINL) (XRTX) (AE) Lower
StreetInsider.com  Mar 30  Comment 
Sunesis Pharmaceuticals (Nasdaq: SNSS) 25.4% HIGHER; Sunesis and Royalty Pharma announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis' lead product...
Morning Movers 03/30: (SNSS) (BONE) Higher; (FINL) (IOC) (OREX) (XRTX) Lower
StreetInsider.com  Mar 30  Comment 
Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement
Globe Newswire  Mar 29  Comment 
SOUTH SAN FRANCISCO, Calif., March 29, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals (Nasdaq:SNSS) and Royalty Pharma today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful
Sunesis Pharmaceuticals (SNSS) Awarded $25 Million in From Royalty Pharma
StreetInsider.com  Mar 29  Comment 
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results and Highlights
Globe Newswire  Mar 14  Comment 
SOUTH SAN FRANCISCO, Calif., March 14, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the fourth quarter and year ended December 31, 2011. Net loss for the three months and year ended
Sunesis to Host Conference Call on March 14th to Discuss Fourth Quarter and Full-Year 2011 Financial Results
Globe Newswire  Mar 8  Comment 
SOUTH SAN FRANCISCO, Calif., March 8, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Wednesday March 14th, 2012 at 10:30 a.m. Eastern Time to discuss corporate updates and
Sunesis to Present at the Cowen and Company 32nd Annual Health Care Conference
Globe Newswire  Feb 29  Comment 
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the Cowen and Company 32nd Annual Health Care
Sunesis to Present at Upcoming Investor Conferences
Globe Newswire  Feb 21  Comment 
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Daniel Swisher, Chief Executive Officer of Sunesis, will




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Sunesis_Pharmaceuticals_(SNSS)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki